Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome

Inclusion Criteria: 1\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis. 3\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol/L or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol/L. Exclusion Criteria: 1. Left main coronary artery disease or severe three-vessel disease; 2. Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors; 3. Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment; 4. The baseline LDL-C was relatively high (LDL-C≥2.6 mmol/L in those taking statins and ≥4.9 mmol/L in those not taking statins). 5. Familial hypercholesterolemia; 6. Known allergy/intolerance to lipid-lowering drugs used in the trial; 7. Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy; 8. Pregnant or breastfeeding female patients.